metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | metastatic/advanced RCC (mRCC) - 2nd line (L2) | |||
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 negative | mRCC - L1 - PDL1 positive | metastatic/advanced RCC (mRCC) - 2nd line (L2) | |
immune chekpoint inhibitors | |||||
anti-PD-(L)1 | |||||
atezolizumab based treatment | |||||
atezolizumab alone | IMmotion-150 ... | IMmotion-150 ... | |||
atezolizumab plus bevacizumab | IMmotion-150 ... | IMmotion-150 ... | |||
atezolizumab plus cabozantinib | CONTACT-03 | ||||
avelumab based treatment | |||||
avelumab plus axitinib | JAVELIN Renal 101 ... | JAVELIN Renal 101... | |||
nivolumab based treatment | |||||
nivolumab alone | CheckMate 025 | ||||
nivolumab plus cabozantinib | CheckMate 9ER | ||||
pembrolizumab based treatment | |||||
pembrolizumab alone | |||||
pembrolizumab plus axitinib | KEYNOTE-426 | ||||
pembrolizumab plus lenvatinib | KEYNOTE-581/CLEAR ... | ||||
Immune checkpoint association | |||||
nivolumab plus ipilimumab | CheckMate 214 ... CheckMate 214 ... CheckMate 214 ... |